AstraZeneca shares: should I buy now?

AstraZeneca shares have done well in recent years, but have not risen on the Covid-19 vaccine news. Edward Sheldon looks at the investment case today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The last time I analysed AstraZeneca (LSE:AZN) shares was all the way back in April 2018. At the time, Neil Woodford had just sold the FTSE 100 pharmaceutical stock. I said, however, that it was worth holding on to.

Holding AZN shares was certainly the right move. Since that article, AstraZeneca’s share price has risen from 5,400p to 7,800p – a gain of around 44%. At one point in July, the share price was above 10,000p.

Would I buy AstraZeneca shares today though? Let’s take a look at the investment case.

AstraZeneca: the investment case

In today’s world, in which global populations are ageing and the burden of disease is increasing, I see AstraZeneca as well positioned for growth. Its areas of focus (Oncology; Cardiovascular, Renal and Metabolism; and Respiratory diseases) are all highly relevant today. And with a portfolio of speciality and primary care medicines, a global presence, and strength in the emerging markets, it looks well placed for success.

Of course, I can’t write an article about AstraZeneca and not discuss its Covid-19 vaccine. News that the group has developed a vaccine, in conjunction with Oxford University, is certainly exciting. However, this may not be the game-changer that some investors were hoping for. This is due to the fact that AZN has promised not to profit from the vaccine during the pandemic. The company’s approach has been to treat the development of the vaccine as a response to a global public health emergency and not a commercial opportunity. This explains why the share price hasn’t surged higher recently.

Revenue is climbing

Turning to the financials, AstraZeneca’s top-line growth has picked up recently, after stagnating for several years. Revenue in 2019 was $24.38bn, up from $22.09bn in 2018.

Looking ahead, City analysts forecast revenue of $26.43bn this year and $29.89bn next year, which is encouraging. Profits are also expected to rise. Last year, AZN’s net profit was $1.3bn. This year and next year, analysts forecast net profit of $5.3bn and $6.7bn respectively. This is all quite positive. 

Balance sheet issues

There are some issues that concern me, however. One is the level of debt on the company’s balance sheet. At 30 September, this stood at $13.76bn. Total equity was $13.62bn. This debt-to-equity ratio is a little higher than I like to see.

The second is the valuation. Currently, AZN’s P/E ratio is 25.5 using this year’s earnings forecast. It falls to 20.7 using next year’s forecast. These valuations are not outrageously high. But they probably don’t leave a lot of room for error.

My view on AZN today

Weighing everything up, I continue to see AstraZeneca shares as a hold today.

If I owned the shares (I don’t), I’d hold on to them. If I didn’t, I’d keep them on my watchlist for now with a view to buying at a slightly cheaper valuation.

At the moment, I think there are probably better stocks to buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »